Document:

Exhibit 104 Mfg Services Agreement

		

			Exhibit 10.4

		

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
			AMENDMENT NO. 3
TO
MANUFACTURING SERVICES AGREEMENT
		

		
			THIS AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 3”) is made as of December 9th, 2015, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza”).
		

		
			WITNESSETH:
		

		
			WHEREAS, Customer and Lonza are party to that certain Manufacturing Services Agreement, dated as of April 13, 2014, (the “Agreement”).
		

		
			WHEREAS, the parties wish to amend the Agreement as more fully set forth herein;
		

		
			NOW, THEREFORE, for and in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
		

			
	
			
				 1.
			Capitalized terms used in this Amendment No. 3 and not otherwise defined herein shall have the respective meanings set forth in the Agreement.

			
	
			
				 2.
			The Agreement is hereby amended to add Appendix C attached hereto, effective as of the date first above written.  The attached Appendix C supersedes any previous version of Appendix C.

			
	
			
				 3.
			Except as expressly set forth in this Amendment No. 3, the terms and conditions of the Agreement shall remain in full force and effect.

		
			IN WITNESS WHEREOF, each of the parties hereto has executed, or has caused its duly authorized officer to execute, this Amendment No. 3 as of the date first above written.
		

			
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						SciClone Pharmaceuticals International Ltd.

					
					
						Lonza Sales Ltd.

				
	
					
						﻿

					
					
						 

				
	
					
						By: /s/ Friedhelm Blobel

					
					
						By: /s/ Albert Pereda

				
	
					
						Name: Friedhelm Blobel

					
					
						Name: Albert Pereda

				
	
					
						Title: Director

					
					
						Title: Legal Counsel

				
	
					
						﻿

					
					
						 

				
	
					
						﻿

					
					
						By: /s/ Michael Maskus

				
	
					
						﻿

					
					
						Name: Michael Maskus

				
	
					
						﻿

					
					
						Title: Associate Director Commercial

				
	
					
						﻿

					
					
						Development

				

		
			﻿
		

		
			 
		

		

		

		 

 

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		EXHIBIT C
		

		
			SPECIFICATIONS
		

		
			﻿
		

		
			Bulk Thymalfasin API (Thymosin Alpha 1)
		

		
			Purity ([***]) [***]% or greater, with no single impurity greater than [***]%.
		

		
			﻿
		

		
			﻿Exhibit 105 Amendment No 4

		

			Exhibit 10.5

		

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
			
		

		
			﻿
		

		
			AMENDMENT NO. 4
		

		
			TO
		

		
			MANUFACTURING SERVICES AGREEMENT
		

		
			THIS AMENDMENT NO. 4 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 4”) is made as of May 31, 2016, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza’’).
		

		
			WITNESSETH:
		

		
			WHEREAS, Customer and Lonza are party to that certain Manufacturing Services Agreement, dated as of April 30, 2014, (as amended, the “Agreement”); and
		

		
			WHEREAS, Customer and Lonza wish to amend the Agreement as more fully set forth herein;
		

		
			NOW, THEREFORE, for and in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows;
		

			
	
			
				 1.
			

			
	
			
			Capitalized terms used in this Amendment No. 4 and not otherwise defined herein shall have the respective meanings set forth in the Agreement.

			
	
			
				 2.
			

			
	
			
			Section 6.4 is deleted in its entirety and replaced with the following:

		
			During each calendar year, Customer undertakes to place Purchase Orders with Lonza (each for delivery during the following calendar year) for a total volume of Product not less than [***].  If Customer fails to purchase such minimums, Customer shall pay the Price per Batch for the number of Batches below the applicable minimum within [***] days following the applicable calendar year end. For the avoidance of doubt, Purchase Orders cancelled by Customer pursuant to Section 6.6 will not be considered purchases for purposes of the foregoing sentence, notwithstanding payment of applicable the Cancellation Fee.
		

		 

		

			 

		

 

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

			
	
			
				 3.
			

			
	
			
			The first sentence of Section 14.1 is deleted and replaced with the following:

		
			This Agreement shall commence on the Effective Date and shall end on April 30, 2026 unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the “Term”).
		

			
	
			
				 4.
			

			
	
			
			Section 14.2.1 is deleted in its entirety and replaced with the following: by either Party for any reason upon [***] months prior written notice to the other Party;

			
	
			
				 5.
			

			
	
			
			The Pricing Section table set forth in Appendix A, Project Plan SL-001 is deleted in its entirety and replaced with the following:

		
			[***]
		

			
	
			
				 6.
			

			
	
			
			Remainder of Agreement.  Except as modified by this Amendment No. 4, all other terms and provisions of the Agreement, as amended, shall remain in full force and effect in accordance with their terms.

			
	
			
				 7.
			

			
	
			
			Entire Agreement This Amendment No. 4 and the Agreement supersede all other prior agreements, understandings, representations and warranties, oral or written between the parties hereto in respect of the subject matter hereof.

		
			IN WITNESS WHEREOF, each of the parties hereto has executed, or has caused its duly authorized officer to execute, this Amendment No. 4 as of the date first above written.
		

			
					
						﻿

					
					
						 

				
	
					
						SciClone Pharmaceuticals International Ltd.

					
						By:  /s/ Richard Harris

					
					
						Lonza Sales Ltd

					
						By: /s/ Marie Leblanc

				
	
					
						Name:  Richard Harris

					
					
						Title: Associate Director Key Account

				
	
					
						Title: Director

					
					
						Management

				
	
					
						﻿

					
					
						 

				
	
					
						﻿

					
					
						By: /s/ Raffael Beck

				
	
					
						﻿

					
					
						Name: Raffael Beck

				
	
					
						﻿

					
					
						Title: Legal Counsel

				

		
			﻿
		

		 

		

			2Exhibit

        

Exhibit 10.13

February 28, 2017

Steven C. McPhail

Dear Steve:

This updated terms of employment letter supersedes and replaces your prior offer letter, dated April 1, 2015. As of the date hereof, you are serving as Chief Commercial Officer of Fluidigm Corporation (“Fluidigm” or the “Company”), reporting directly to the Chief Executive Officers.  Other terms of employment include:

Compensation:  
Your current annual base salary is $339,700, which will be paid, less any deductions required by applicable law, in accordance with the Company’s normal payroll procedures.  The Company is on a semi-monthly pay schedule with two pay periods per calendar month which generally fall on the 15th and the last day of the month. This is an exempt position.  

Executive Bonus Plan:
You will be eligible to participate in the Company’s Executive Corporate Bonus Plan which is based on achievement of targets or performance criteria as may be specified by your management and the Board. The terms and conditions of the Bonus Plan may be amended or varied from time to time at the sole discretion of the Board.  Your target bonus is currently 42.5% of your annual base salary, subject to all applicable federal and state taxes, which, if and to the extent earned, is typically paid out following the end of the applicable bonus year.  

Equity Award:
As you know, you have been granted certain equity awards under the Company equity incentive plan; such outstanding awards remain subject to the terms of the plan and the relevant grant documents.  You may be eligible, subject to approval by the Company’s Board of Directors or its Compensation Committee, for further awards depending on performance and other considerations in the discretion of the Company.

Benefits:
You are eligible to receive the Company’s standard benefits package which includes medical, dental, vision, life and disability insurance benefits.  Benefits will be effective the first day of the month following your date of hire or upon a qualifying event.  Additional benefits, as the Company may make generally available to its employees from time to time, will be made available to you.   You are entitled to three (3) weeks paid vacation each year and such paid holidays as the Company gives to its employees generally.

Workers’ Compensation Insurance:
The Company provides a comprehensive workers’ compensation insurance program at no cost to employees.  This program covers any injury or illness sustained in the course of employment that requires medical, surgical or hospital treatment.  Insurance carrier:  Preferred Employers Group - PO BOX 85838, San Diego, CA 92186, phone number (866) 472-9602.

1

        

Confidentiality and Company Policies:  
You have executed the Company’s standard At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement, which continues to be in effect.

Employment and Severance Agreement:
As an executive officer of the Company and subject to approval by the Board (or a committee authorized by the Board), you and the Company have entered into the Company’s Employment and Severance Agreement.  A copy of the current form of such agreement as entered between the Company and each of its executive officers has been provided to you separately.  

Other:
This letter shall be interpreted under California law.  You should be aware that your employment with the Company is for no specified period and constitutes “at will” employment.  As a result, you are free to resign at any time, for any reason or for no reason.  Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause.  In addition, the Company may change your compensation, duties, assignments, responsibilities, location of your position, or any other terms and conditions of employment at any time to adjust to the changing needs of our dynamic Company.

In the event of any dispute or claim relating to or arising out of our employment relationship, you and the Company agree that all such disputes shall be fully and finally resolved by binding arbitration conducted by the Judicial Arbitration & Mediation Services (“JAMS”) in Santa Clara County California. The current JAMS employment arbitration rules & procedures can be found at http://www.jamsadr.com/rules-employment-arbitration/.  The JAMS employment arbitration rules & procedures may, however, be amended by JAMS.) You acknowledge that you are waiving your right to a jury trial.

Our employees are committed to the success and growth of our business.  At Fluidigm, we believe that our values are not just words on paper – they are a statement of our character.  Fluidigmers should:  Win as a team; Work hard and with passion; Be strong; Be aggressive; Do what you say you will do; Sweat the details; and Keep learning.  We believe our values define who we are as a company and as employees of Fluidigm.  We aspire to live by these values each day and work hard to exhibit these traits because these are the things that are worth believing.  Thank you for your continued dedication to Fluidigm; I look forward to our mutual success in growing the Company.
 

2

        

	
			
	Sincerely,
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ S. Christopher Linthwaite
	 
	 

	 
	 
	 

	S. Christopher Linthwaite 
	 
	 

	President and CEO 
	 
	 

	Fluidigm Corporation
	 
	 

	 
	 
	 

	 
	 
	 

	ACCEPTED AND AGREED TO:
	 
	 

	 
	 
	 

	 
	 
	 

	/s/ Steven C. McPhail
	 
	February 28, 2017

	Steven C. McPhail
	 
	Date

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]